Mersana Therapeutics, Inc.
MRSN
$0.3659
$0.00982.75%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -83.17% | 29.87% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -83.17% | 29.87% | |||
| Cost of Revenue | -17.70% | 50.55% | |||
| Gross Profit | -163.07% | -168.71% | |||
| SG&A Expenses | 0.44% | -9.91% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -12.53% | 26.37% | |||
| Operating Income | -65.50% | -22.72% | |||
| Income Before Tax | -70.88% | -27.38% | |||
| Income Tax Expenses | -- | -100.00% | |||
| Earnings from Continuing Operations | -70.88% | -22.75% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -70.88% | -22.75% | |||
| EBIT | -65.50% | -22.72% | |||
| EBITDA | -67.90% | -23.52% | |||
| EPS Basic | -69.55% | -21.99% | |||
| Normalized Basic EPS | -69.61% | -26.60% | |||
| EPS Diluted | -69.55% | -21.99% | |||
| Normalized Diluted EPS | -69.61% | -26.60% | |||
| Average Basic Shares Outstanding | 0.73% | 0.68% | |||
| Average Diluted Shares Outstanding | 0.73% | 0.68% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||